請輸入關鍵字:

熱門搜尋:

Arthur D. Little Report Explores Impact of “Ultra-targeted” Healthcare

日期: 2019年5月7日 下午4:15

All segments of healthcare will need to adapt to unprecedented change driven by technological advancements in areas such as molecular biology, AI and digitalization

BOSTON--(BUSINESS WIRE)-- As pivotal changes in healthcare and drug development gain traction, new analysis from Arthur D. Little (ADL) highlights that all sectors of the industry must evolve their business and operating models in the coming decade.

From genomic treatments to Artificial Intelligence in diagnostics to leaps in curative medicine, the healthcare ecosystem is facing unprecedented change. ADL’s forward-looking assessment is captured in a new Report, “Future Health: How the industry will move from ‘one size fits all’ to ultra-targeted care.”

Several critical shifts are pushing major players across the world to adapt:

  • Targeted treatments are changing the way drugs are brought to market, with greater emphasis on patients’ biological make-ups. Already, 22% of drugs currently in development specify a biomarker as criteria for inclusion, according to ADL research.
  • ADL projects the global consumer genetic testing market will reach $50B by 2026, leading to an abundance of genomic data that will be available to guide prevention, diagnosis, and treatment.
  • Certain chronic diseases will become more curable or treatable, and patients with access to more data will have greater opportunity to prevent or manage their conditions.
  • Long-term care will continue to shift away from hospitals, which will in turn move their model from surgeries and long-term chronic care to a physician-led approach to curative therapies, and may lead them to consider onsite device and drug manufacturing.

Craig Wylie, Managing Partner at ADL in the United States, notes: “Incredible advances in genomics and diagnostics are leading to a future that will impact the entire breadth of the healthcare industry. Companies are in the early stages of evolving their approach to clinical trials, commercial models, and care provision.”

“The pace of change and the associated costs will be staggering,” continued Wylie. “The most successful organizations across all segments of the healthcare ecosystem will be those that adapt their business models, rethink their operations, and place an emphasis on collaboration and partnerships.”

To download the Report, please visit: www.adl.com/FutureHealth

Contacts

Cate Bonthuys
Catalyst Comms
cate@catalystcomms.co.uk
Tel: +44 7746546773

財華網所刊載內容之知識產權為財華網及相關權利人專屬所有或持有。未經許可,禁止進行轉載、摘編、複製及建立鏡像等任何使用。

如有意願轉載,請發郵件至 content@finet.com.hk,獲得書面確認及授權後,方可轉載。

下載APP 下載財華財經APP,把握投資先機
更多精彩内容,請點擊: 財華網(https://www.finet.hk/) 財華智庫網(https://www.finet.com.cn) 現代電視FINTV(http://www.fintv.hk)

視頻

快訊

17:35
中國海洋石油(00883.HK):中國海油集團已累計約6.52億人民幣增持股份
17:27
信利國際(00732.HK)9月綜合營業淨額同比減少16.3%
17:20
香港聯交所:坤集團(00924.HK)上市地位自10月13日起取消
17:06
香港聯交所:愛帝宮(00286.HK)上市地位自10月13日起取消
16:59
證監會、會財局及聯交所聯手應對上市發行人「僅因持續經營問題被出具無法表示意見」個案增加
16:54
保利置業集團(00119.HK)9月合同銷售額約35億元
16:48
石四藥集團(02005.HK)尼莫地平口服溶液獲藥品生產註冊批件
16:20
【異動股】港股跌幅榜前十,友芝友生物-B(02496.HK)跌30.88%,法拉帝(09638.HK)跌26.97%
16:20
【異動股】港股漲幅榜前十,米蘭站(01150.HK)漲+78.79%,朝威控股(08572.HK)漲+44.93%
16:19
許正宇考察瑞士頂尖黃金精煉廠 推動落戶香港和擴充業務